DYNLL1 and esophageal squamous cell carcinoma: These in vivo findings mechanistically converge with our molecular data, demonstrating that EVs-encapsulated DYNLL1-AS1 orchestrates PD-L1-dependent immune evasion through dual modulation of TAMs checkpoint expression, thereby establishing a therapeutically targetable axis in radioresistant ESCC.